RxDoctor Payments Data

Hamid Habibi, MD

Gastroenterology · Spokane, WANPI 1194018366

Payments from drug & device makers

$1,823in general payments, 2019–2025

Across 80 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$907
  • Pfizer$202
  • Bristol Myers Squibb$151
  • Takeda Pharmaceuticals U.S.A., Inc.$110
  • Boston Scientific$99
  • Johnson & Johnson$73
  • plus $279 from 8 others

What the payments were for

  • Food & beverage$1,72094%
  • Education$1036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,823 in reported general payments places this provider in the 65th percentile of 447 gastroenterology providers in Washington.

See all gastroenterology providers in Washington

Medicare billing

Part B allowed, 2024
$347,629
Medicare patients
361
Services billed
11,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate15$100,732
Humira(Cf) PenAdalimumab13$86,930
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates189$11,486
Dexlansoprazole DrDexlansoprazole17$6,299
Mesalamine28$6,019
Omeprazole299$4,960
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl219$3,836
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,089
Lansoprazole30$2,057
Budesonide DrBudesonide14$1,348
SuprepSodium, Potassium,mag Sulfates11$975
Pantoprazole Sodium62$772
Sulfasalazine26$728
Famotidine60$604
Azathioprine16$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$202$100,73215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 447 gastroenterology providers in Washington.

Other gastroenterology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →